Pfizer’s Xeljanz (tofacitinib) Receives US FDA’s Approval for the Treatment of Active Ankylosing Spondylitis
Shots:
- The approval is based on the P-III study to evaluate the efficacy & safety of tofacitinib (5mg, bid) vs PBO in 269 adult patients with active AS who have had an inadequate response or intolerance to one or more TNF blockers
- The study met its 1EPs i.e., @16wks., the proportion of patients treated with tofacitinib achieved an assessment in ASAS 20 response (56.4% vs 29.4%) while patients achieved an ASAS40 response (40.6% vs 12.5%). The safety profile was consistent with the safety profile observed in RA & PsA
- Xeljanz is the 1st oral JAK inhibitor approved in the US in 5 indications i.e., AS, RA, active PsA, UC & pcJIA. The therapy has been studied in 50+ clinical trials globally
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com